These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 22088976

  • 1. Investigation of the insulin-like properties of zinc(II) complexes of 3-hydroxy-4-pyridinones: identification of a compound with glucose lowering effect in STZ-induced type I diabetic animals.
    Moniz T, Amorim MJ, Ferreira R, Nunes A, Silva A, Queirós C, Leite A, Gameiro P, Sarmento B, Remião F, Yoshikawa Y, Sakurai H, Rangel M.
    J Inorg Biochem; 2011 Dec; 105(12):1675-82. PubMed ID: 22088976
    [Abstract] [Full Text] [Related]

  • 2. Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin-mimetic activities.
    Yamaguchi M, Wakasugi K, Saito R, Adachi Y, Yoshikawa Y, Sakurai H, Katoh A.
    J Inorg Biochem; 2006 Feb; 100(2):260-9. PubMed ID: 16387366
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of insulin-mimetic activities of vanadyl and zinc(II) complexes from the viewpoint of heterocyclic bidentate ligands.
    Katoh A, Matsumura Y, Yoshikawa Y, Yasui H, Sakurai H.
    J Inorg Biochem; 2009 Apr; 103(4):567-74. PubMed ID: 19162327
    [Abstract] [Full Text] [Related]

  • 4. The pharmacology of the insulinomimetic effect of zinc complexes.
    Sakurai H, Adachi Y.
    Biometals; 2005 Aug; 18(4):319-23. PubMed ID: 16158223
    [Abstract] [Full Text] [Related]

  • 5. Insulinomimetic bis(maltolato)zinc(II) complex: blood glucose normalizing effect in KK-A(y) mice with type 2 diabetes mellitus.
    Yoshikawa Y, Ueda E, Miyake H, Sakurai H, Kojima Y.
    Biochem Biophys Res Commun; 2001 Mar; 281(5):1190-3. PubMed ID: 11243860
    [Abstract] [Full Text] [Related]

  • 6. Development of new insulinomimetic zinc(II) picolinate complexes with a Zn(N2O2) coordination mode: structure characterization, in vitro, and in vivo studies.
    Yoshikawa Y, Ueda E, Kawabe K, Miyake H, Takino T, Sakurai H, Kojima Y.
    J Biol Inorg Chem; 2002 Jan; 7(1-2):68-73. PubMed ID: 11862542
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic properties of VO(dmpp)2 as assessed by in vitro and in vivo studies in type 2 diabetic GK rats.
    Domingues N, Pelletier J, Ostenson CG, Castro MM.
    J Inorg Biochem; 2014 Feb; 131():115-22. PubMed ID: 24333827
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Study of the antidiabetic capacity of the VO(dmpp)2 complex.
    Passadouro M, Metelo AM, Melão AS, Pedro JR, Faneca H, Carvalho E, Castro MM.
    J Inorg Biochem; 2010 Sep; 104(9):987-92. PubMed ID: 20627316
    [Abstract] [Full Text] [Related]

  • 11. The action mechanism of zinc(II) complexes with insulinomimetic activity in rat adipocytes.
    Yoshikawa Y, Ueda E, Kojima Y, Sakurai H.
    Life Sci; 2004 Jun 25; 75(6):741-51. PubMed ID: 15172182
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A family of insulinomimetic zinc(II) complexes of amino ligands with Zn(Nn) (n=3 and 4) coordination modes.
    Yoshikawa Y, Kondo M, Sakurai H, Kojima Y.
    J Inorg Biochem; 2005 Jul 25; 99(7):1497-503. PubMed ID: 15921760
    [Abstract] [Full Text] [Related]

  • 14. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
    Novelli M, D'Aleo V, Lupi R, Paolini M, Soleti A, Marchetti P, Masiello P.
    Pancreas; 2007 Nov 25; 35(4):e10-7. PubMed ID: 18090226
    [Abstract] [Full Text] [Related]

  • 15. Orally active and long-term acting insulin-mimetic vanadyl complex:bis(picolinato)oxovanadium (IV).
    Sakurai H, Fujii K, Watanabe H, Tamura H.
    Biochem Biophys Res Commun; 1995 Sep 25; 214(3):1095-101. PubMed ID: 7575515
    [Abstract] [Full Text] [Related]

  • 16. Bis(allixinato)oxovanadium(IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes.
    Adachi Y, Yoshida J, Kodera Y, Katoh A, Takada J, Sakurai H.
    J Med Chem; 2006 Jun 01; 49(11):3251-6. PubMed ID: 16722643
    [Abstract] [Full Text] [Related]

  • 17. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
    Márquez L, González N, Puente J, Valverde L, Villanueva-Peñacarrillo ML.
    Diabetes Nutr Metab; 2001 Oct 01; 14(5):239-44. PubMed ID: 11806463
    [Abstract] [Full Text] [Related]

  • 18. Insulinomimetic Zn(II) complexes as evaluated by both glucose-uptake activity and inhibition of free fatty acids release in isolated rat adipocytes.
    Nishide M, Yoshikawa Y, Yoshikawa EU, Matsumoto K, Sakurai H, Kajiwara NM.
    Chem Pharm Bull (Tokyo); 2008 Aug 01; 56(8):1181-3. PubMed ID: 18670123
    [Abstract] [Full Text] [Related]

  • 19. Effect of new and known 1,4-dihydropyridine derivatives on blood glucose levels in normal and streptozotocin-induced diabetic rats.
    Briede J, Stivriņa M, Stoldere D, Bisenieks E, Uldriķis J, Poikāns J, Makarova N, Duburs G.
    Cell Biochem Funct; 2004 Aug 01; 22(4):219-24. PubMed ID: 15248181
    [Abstract] [Full Text] [Related]

  • 20. The plasma glucose lowering action of tetrandrine in streptozotocin-induced diabetic rats.
    Chen WC, Hayakawa S, Yamamoto T, Huang LW, Liu IM, Cheng JT.
    J Pharm Pharmacol; 2004 May 01; 56(5):643-8. PubMed ID: 15142342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.